BIOCON | DR. REDDYS LAB | BIOCON / DR. REDDYS LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 36.7 | 24.1 | 152.2% | View Chart |
P/BV | x | 4.6 | 3.7 | 123.4% | View Chart |
Dividend Yield | % | 0.2 | 0.7 | 22.6% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-22 |
DR. REDDYS LAB Mar-22 |
BIOCON / DR. REDDYS LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 424 | 5,614 | 7.6% | |
Low | Rs | 315 | 3,655 | 8.6% | |
Sales per share (Unadj.) | Rs | 68.2 | 1,294.6 | 5.3% | |
Earnings per share (Unadj.) | Rs | 8.2 | 126.9 | 6.4% | |
Cash flow per share (Unadj.) | Rs | 14.9 | 196.9 | 7.6% | |
Dividends per share (Unadj.) | Rs | 0.50 | 30.00 | 1.7% | |
Avg Dividend yield | % | 0.1 | 0.6 | 20.9% | |
Book value per share (Unadj.) | Rs | 68.5 | 1,145.8 | 6.0% | |
Shares outstanding (eoy) | m | 1,200.60 | 166.43 | 721.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.4 | 3.6 | 151.4% | |
Avg P/E ratio | x | 45.3 | 36.5 | 124.2% | |
P/CF ratio (eoy) | x | 24.7 | 23.5 | 105.2% | |
Price / Book Value ratio | x | 5.4 | 4.0 | 133.3% | |
Dividend payout | % | 6.1 | 23.6 | 26.0% | |
Avg Mkt Cap | Rs m | 443,622 | 771,272 | 57.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 18,801 | 38,858 | 48.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 81,840 | 215,452 | 38.0% | |
Other income | Rs m | 6,891 | 4,847 | 142.2% | |
Total revenues | Rs m | 88,731 | 220,299 | 40.3% | |
Gross profit | Rs m | 13,827 | 37,674 | 36.7% | |
Depreciation | Rs m | 8,142 | 11,652 | 69.9% | |
Interest | Rs m | 676 | 958 | 70.6% | |
Profit before tax | Rs m | 11,900 | 29,911 | 39.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,115 | 8,789 | 24.1% | |
Profit after tax | Rs m | 9,785 | 21,122 | 46.3% | |
Gross profit margin | % | 16.9 | 17.5 | 96.6% | |
Effective tax rate | % | 17.8 | 29.4 | 60.5% | |
Net profit margin | % | 12.0 | 9.8 | 122.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 83,823 | 177,880 | 47.1% | |
Current liabilities | Rs m | 38,280 | 97,658 | 39.2% | |
Net working cap to sales | % | 55.6 | 37.2 | 149.5% | |
Current ratio | x | 2.2 | 1.8 | 120.2% | |
Inventory Days | Days | 101 | 56 | 180.6% | |
Debtors Days | Days | 92 | 113 | 81.2% | |
Net fixed assets | Rs m | 117,184 | 106,819 | 109.7% | |
Share capital | Rs m | 6,003 | 832 | 721.5% | |
"Free" reserves | Rs m | 76,281 | 189,859 | 40.2% | |
Net worth | Rs m | 82,284 | 190,691 | 43.2% | |
Long term debt | Rs m | 39,985 | 5,746 | 695.9% | |
Total assets | Rs m | 201,007 | 284,699 | 70.6% | |
Interest coverage | x | 18.6 | 32.2 | 57.7% | |
Debt to equity ratio | x | 0.5 | 0 | 1,612.7% | |
Sales to assets ratio | x | 0.4 | 0.8 | 53.8% | |
Return on assets | % | 5.2 | 7.8 | 67.1% | |
Return on equity | % | 11.9 | 11.1 | 107.4% | |
Return on capital | % | 10.3 | 15.7 | 65.5% | |
Exports to sales | % | 0 | 47.1 | 0.0% | |
Imports to sales | % | 7.8 | 18.8 | 41.4% | |
Exports (fob) | Rs m | NA | 101,544 | 0.0% | |
Imports (cif) | Rs m | 6,360 | 40,401 | 15.7% | |
Fx inflow | Rs m | 8,885 | 101,544 | 8.7% | |
Fx outflow | Rs m | 6,360 | 40,401 | 15.7% | |
Net fx | Rs m | 2,525 | 61,143 | 4.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,766 | 28,108 | 41.9% | |
From Investments | Rs m | -16,991 | -26,387 | 64.4% | |
From Financial Activity | Rs m | 2,421 | -2,422 | -100.0% | |
Net Cashflow | Rs m | -2,433 | 32 | -7,603.1% |
Indian Promoters | % | 39.7 | 26.7 | 148.7% | |
Foreign collaborators | % | 20.9 | 0.0 | - | |
Indian inst/Mut Fund | % | 24.0 | 51.1 | 47.1% | |
FIIs | % | 16.3 | 25.9 | 63.0% | |
ADR/GDR | % | 0.0 | 10.4 | - | |
Free float | % | 39.4 | 62.9 | 62.6% | |
Shareholders | 341,016 | 255,300 | 133.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: SUN PHARMA CIPLA LUPIN ZYDUS LIFESCIENCES AUROBINDO PHARMA
Indian share markets traded in a rangebound manner throughout the day to end on a flat note.